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 Abstract 
 
Cardiovascular disease (CVD) is the major cause of death globally; therefore, there is a need 
for the identification of valid biomarker that accurately predict the risk of developing 
cardiovascular disease, and novel therapeutic approaches for its treatment. Exosomes are very 
small extracellular vesicles containing protein, lipid, transcription factors, mRNAs, non-coding 
RNA and nucleic acid contents, that are important players in intercellular communication, and 
that act via long-range signals or cell-to-cell contact. The discovery of exosomes provides 
potential strategies for the diagnosis and treatment of cardiovascular disease. In the current 
review, we have explored the potential impact of exosomes on cardiovascular physiology, and 
their therapeutic potential in cardiovascular disorders with a emphasize on the existing 
preclinical studies. 
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 Introduction  
    Cardiovascular disease (CVD) is a chronic disorder which is very common worldwide. 
Atherosclerosis, myocardial infraction (MI) and stroke are most prevalent categories of CVD (1). 
There are several classical risk factors contributing to the pathogenesis of CVD including age, 
sex, diabetes (2), cigarette smoking, systolic and diastolic blood pressure, and dyslipidemia (3).  
    Various types of cell therapy, including stem cells and cardiosphere-derived cells (CDC) have 
been used for promoting the repair and regeneration after CVD (4). A variety of cell types 
including embryonic stem cells, foetal cardiomyocytes and human umbilical cord-derived cells 
have been used as potential cell candidates for cardiac repair (5). Cardiopoietic stem cell 
therapy has been used in heart failure (HF) (C-CURE) as a potential new treatment for patients 
with HF of ischemic origin has been used, and myocardial remodeling, left ventricular ejection 
fraction (LVEF) levels were reduced by cell therapy (6). CDCs have recently been used for the 
treatment of heart failure and was also found to stimulate regeneration, angiogenesis and 
functional improvement (7). Mentowski et al engineered CDC-derived exosome, as an 
extracellular vesicle that was used to transport signaling molecules that play a critical role in 
intercellular communication, and expressed Lamp-2, an exosomal transmembrane protein. This 
was fused to a cardiomyocyte-specific peptide, to investigate the therapeutic potential of 
appropriate delivery to the heart. They have proposed that increasing the uptake of exosomes 
derived from CDCs by cardiomyocyte may be a suitable target for anti-apoptotic drug and gene 
therapy (8).  
   Furthermore, intercellular communication plays an important role in the survival and 
homeostatic cellular mechanisms. Intercellular communication can occur via direct contact or by 
signaling molecules secreted by cells. Gap junction proteins and cell surface interactions are 
important components of direct contact between cell-cell. These proteins can directly connect 
two cells through cytoplasmic domains which leads to intracellular metabolite exchanges. 
Secreted signaling molecules including hormones, neurotransmitters and cytokines, bind to 
specific receptors which trigger specific cellular responses. Cell-cell communication can occur 
via another communication mechanism termed extracellular vesicle (EVs). These are released 
by, taken up by the cell membrane. The extracellular vesicle can deliver different signals to 
target cell via the binding of ligands to different cell surface receptors, delivering surface 
receptors and transferring signaling molecules such as lipids, proteins and RNAs (9). Three 
types of these vesicles are involved in various cellular processes, including: apoptotic vesicles, 
microvesicles and exosomes (10). Exosomes may fuse with endosomes to form complex 
structure named multivesicular bodies (MVBs). In turn, the fusion of these structures with 
cellular membrane results in the release of exosomes from these vesicles (11). The exosomes 
are nanosized secreted vesicles, which can execute intercellular communications, because they 
transport signaling molecules that include mRNA, siRNA and protein (12) (figure 1). 
    There has been increasing interest on the role of exosome composition in the causation of a 
variety of diseases such as cardiovascular disease (13). In addition, it has been shown that 
EVs, such as exosomes, play an important role in the pathogenesis of cardiovascular disease 
(14). Exosomes could also be an attractive biomarker for guiding therapeutic interventions in 
cardiovascular disease (14). Lai et al. examined how exosomes can stimulate the formation of 
mesenchymal stem cells (MSCs) in cardiac disease such as acute myocardial infarction. They 
also suggested that exosomes could be used as a biomarker for therapeutic agent in treatment 
of cardiac disease (15). This review summarizes the possible role of exosomes in the 
pathogenesis of cardiovascular disease including cardiomyopathy, MI, HF, and atherosclerosis. 
 
Exosome formation 
    The fact that exosomes-containing particles may act as intercellular signaling molecules was 
first described in relation to maturation of sheep’s reticulocytes (16). Exosome release from 
reticulocytes, can play a critical role in transferring various signaling molecules to cells or 
tissues. Furthermore, these vesicles have several receptors for other molecular components, for 
example a transferrin receptor. It has also been reported that transferrin receptor-containing 
exosomes can bind to the iron (Fe)-transferrin complex (17). 
    Many studies have showed that exosome formation is related to the destruction of some 
organelles, such as mitochondria and nucleus (18). It has been reported that exosome 
formation is increased following the maturation of reticulocytes via the release proteins that 
include Alix (19) during mitochondria destruction (18). To further support the relationship 
between exosome formation and organelles destruction, Fader et al. demonstrated that during 
differentiation of K562, a human erythroleukemia cell line to the erythrocytes, two factors 
enhance exosome formation that are derived from mitochondria destruction including Rab11, as 
a protein involved in fusion, and calcium (Ca2+) (20). In contrast, it has been demonstrated that 
exosome formation during maturation of avian red cells is independent of mitochondria and 
nucleus destruction (19). It has also been found that differentiation of the erythroblast avian cell 
line to the red cells leads to secretion of transferrin receptor-containing exosome without loss of 
any organelles (21).  
Biology of exosome synthesis and secretion 
Apoptotic vesicles are between 1-4μm in diameter, and contain signaling molecules that are 
destined for the cell membrane, cellular organelles and cytosol (10). Unlike Microvesicles which 
directly release from the plasma membrane, and are between 100nm to 1μm, exosomes with 
budding to endosome vesicles form complex vesicles of MVBs (22). Unlike the two other types 
of extracellular vesicles, exosomal vesicles are between 40-100nm and are released by fusion 
with MVBs with the plasma membrane which is associated with activation of exocytosis 
processes (23).  
    Different methods have been established for exosome formation and sorting of endosomal 
proteins into these vesicles. One of these methods is via the transport (ESCRT) pathway which 
is required for multivesicular bodies formation and sorting of endosomal components (24, 25). 
This transport system comprises several soluble multi-proteins including ESCRT-0, ESCRT-1, 
ESCRT-2, ESCRT-3 and accessory proteins. ESCRT-0 acts as a ubiquitin-dependent manner 
which is required for cargo clustering. ESCRT-1 and -2 can stimulate bud formation, whereas 
ESCRT-3 and accessory proteins such as vacuolar protein-sorting associated protein 4 (VPS4) 
ATPase, classifies vesicles and recruits deubiquitination machinery of the ESCRT system, 
respectively (24). It has been reported that there are 23 ESCRT components and its associated 
proteins may be silenced by using RNA interference which effects the production of antigen-
containing exosomes (26). Some soluble multi-proteins and their associated proteins such as 
hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), TSG101 as an ESCRT-1 
component and STAM1 as an ESCRT-0 components are depleted by RNA interference that 
leads to both a reduction of MHC-ǀǀ-containing exosome production and effects the size and 
signaling molecules of exosome (26). To further support the role of soluble multi-proteins of 
ESCRT system in exosome formation, it has been reported that HRS, an ESCRT-0 component, 
is required both for exosome formation and its antigen-presenting capacity (27). Recently, in a 
study has examined the interaction between cellular components such as syndecan heparan 
sulfate proteoglycans and protein cytoplasmic adaptor of syntenin with protein ALIX, as a 
protein binding of ESCRT-3, and has been found to stimulate both exosome formation and the 
production of exosome-containing signaling molecules, such as CD63 in both primary dendritic 
cells (DCs) and C2C12, a muscle cell line (28, 29). 
    On the other hand, some studies have established that exosome formation is independent of 
the ESCRT transport system and dependent on natural cellular components (30, 31). In support 
of this, it has been reported that exosomes containing proteolipid proteins, tetraspanins and 
heat shock proteins are formed by silencing ALIX, HRS and TSG101 gene expression (32) 
using RNA interference, whereas secretion of some components such as proteolipid protein-
positive exosome are controlled by ceramide production caused by natural sphingomyelinase-2 
(33). In a study, sphingosine-1- phosphate (S1P), as a metabolite of sphingomyelin, are 
important in biogenesis of signaling molecules of exosomes such as CD63, CD81 and flotillin 
(31). In another study, it was shown that choline and phosphatidic acid are produced by 
phospholipase D activation which controls exosome secretion (34). Furthermore, lipid rafts, a 
normal cellular component, play an important role in exosome-sorting proteins (35). Therefore, it 
has been shown that markers of lipid rafts such as flotillin-1 (36), stomatin (37), GM1 and Lyn 
(38) have been identified in exosomes.  
      Exosomes are released by different types of cells in response to various biological and 
chemical stimuli. Rab GTPases (39), Wnt5a (40) and glycosphingolipids (41) are biological 
stimuli that lead to constitutive exosome secretion. Factors such as DNA damage (42), calcium 
release (43), heat shock proteins (44), thrombin (23), hypoxia condition (45), depolarization of 
plasma membrane and lipopolysaccharide (LPS) are chemical stimuli which result in inducible 
exosome secretion from the cell. In line with this, it has been shown that exosomes secretion 
are increased by different stimuli factors including oxidative stress (46), low pH (47) and hypoxia 
(48). It has also been reported that depolarization of plasma membrane caused by K+ result in 
increased exosome release from the neural cells (49). Different factors that include: low levels 
of hydrogen peroxide (H2O2) can induce cardiomyocyte cells to releasing exosome from these 
cells (50). It has been established that changes in the cell environmental, such as ischemia can 
trigger the release of exosomes from the heart (50). 
    Molecules such as DNA, RNA and proteins are components of exosomes which can transfer 
signals to the target cells (51). It has been shown that exosomal proteins are common to the 
protein components of other cellular organelles including plasma membrane, cytosol, Golgi and 
nucleus (52). On the other hand, it has also been reported that lipid components such as 
cholesterol, sphingolipids, glycerophospholipids, phosphatidylcholine and 
phosphatidylethanolamine are highly enriched in exosome membrane compared with plasma 
membrane (53). Furthermore, it has also been demonstrated that exosome membrane is 
enriched of tetraspanins such as CD9, CD63, CD81 and CD82, GPI-anchored proteins and 
tumor necrosis factor receptor 1 (TNFR1) which are known as protein components of 
membrane exosome (54).  
Consistent with these results, we suggested that exosome-containing signaling molecules and 
components changes can be an appropriate factor for examining etiology of diseases such as 
CVD. 
 
Role of exosomes in cardiomyopathy 
    
    Cardiomyopathy or right ventricular dysplasia is a disorder of heart muscle (55) with an 
autosomal dominant mode of inheritance (56).  
    Aminzadeh et al. have shown that human CDCs-secreted exosomes improve the features of 
Duchenne’s cardiomyopathy in mdx mice. They also demonstrated that exosomes released 
from CDCs improve cardiac function and overall survival, as well as enhancing maximal 
exercise capacity by transferring the miR-148a signaling molecule in this model (57). Suzuki 
investigated the protein biomarkers such as fibrinogen gamma chain (FGG) in plasma 
exosomes by mass spectrometry in model of dilated cardiomyopathy (DCM) in 4C30 mouse 
(58). Moreover, Jiang et al. showed that exosomes derived from the serum of children with DCM  
stimulated gene expression-associated pathological changes in human-induced pluripotent 
stem cell-derived cardiomyocyte (iPSC-CMs) and neonatal rat ventricular myocytes (NRVMs) 
(59).  
 Gallet et al. possible use of percutaneous trans-endocardial delivery of CDCs using the NOGA 
MYOSTAR injection catheter in a post-MI cardiomyopathy model in pigs. They demonstrated 
that exosome secretion-related to the CDCs, inhibit left ventricular (LV) adverse remodeling and 
reduce scar mass and scar size in the pigs injected with CDCs (60).  
    Exosomes can improve the changes of cardiovascular system including reducing of Ca 2+ 
response, mitochondrial dysfunction and reduce the response of the β-adrenergic receptor, via 
exosomal components, in septic cardiomyopathy. To further support the role of exosomes in the 
pathogenesis of septic cardiomyopathy, Monteiro et al. demonstrated that exosomes containing 
nicotine adenine dinucleotide phosphate hydrogen (NADPH) induce cell death and cardiac 
dysfunction by internalization of exosomes in endothelial cells in septic cardiomyopathy (61). 
    Recent studies have shown that exosomes containing low heat shock protein 20 (Hsp 20) are 
released from cardiomyocytes derived from diabetics. Wang et al. examined the potential 
protective effect of exosomes containing high levels of Hsp20 against streptozotocin (STZ)-
induced diabetes and adverse cardiac remodeling in a mouse model of cardiac-specific 
overexpression of Hsp20. They demonstrated that over-expression of exosomes derived Hsp20 
attenuates cardiac dysfunction, hypertrophy, fibrosis, apoptosis, and microvascular rarefaction 
in STZ-treated mice, and increases exosomes secretion because of a direct interaction between 
Hsp20 and Tsg101, an initiator of exosome biogenesis in cells (62). Wang et al. also showed 
that exosomes containing high levels of Hsp20, enhance cardiac blood vessel density and 
reduce fibrosis of myocardial in STZ diabetic mice (63). Furthermore, exosomes containing 
Hsp20 stimulate cardiac angiogenesis in myocytes. Furthermore, Gu et al. have reported that 
exosomes containing high concentrations of Hsp20 improve cardiac dysfunction and 
angiogenesis by increasing the interaction between Hsp20 and Tsg101 induced by 
overexpression of Hsp20 in model of STZ-induced diabetic TG and WT mice (64).  
 
The role of exosomes in the atherosclerosis 
   Atherosclerosis is an inflammatory disease that may involve both innate and adaptive immune 
responses. There are several factors regulating the pathogenesis of atherosclerosis including 
immune cells such as monocytes, macrophages, dendritic cells, and lymphocytes, chemokines, 
interleukins, oxidized low-density lipoprotein (LDL) and HPSs (65). 
   Perrotta and Aquila, studied the presence of exosomes in human atherosclerotic plaque using 
transmission electron microscopy. They demonstrated that exosomes are formed by both 
endothelial cells and lesional smooth muscle cells (66).  
   Moreover, exosomes enhance inflammatory responses and vessel infiltration by delivering the 
contents of apoptotic and inflammatory between blood cells and vascular cells in atherosclerosis 
process (67). To further support the role of exosome in atherogenesis, Gao et al. investigated 
the effect of exosomes on endothelial inflammation and atherosclerosis by using a transwell 
model system and exosome release inhibitor GW4869. They stimulated human umbilical vein 
endothelial cell (HUVEC) with dendritic cell-derived exosomes and showed that  exosomes 
secreted by dendritic cells and tumor necrosis factor (TNF)-α on cellular membrane of 
exosomes enhance HUVEC inflammation and atherosclerotic lesion by activation of the nuclear 
factor-κB (NF-κB) signaling pathway (68).  
   Exosomes containing miRNAs play a key role in the pathogenesis of atherosclerosis (69). 
Zheng et al. showed that exosomes containing miR-155 derived from vascular smooth muscle 
cells (VSMCs) stimulate endothelial permeability and progression of atherosclerotic plaque by 
disrupting the tight junctions between endothelial cells, and endothelial barrier integrity, which is 
mediated by over expression of miR-155 induced by krupple-like factor 5 (KLF5), a regulator of 
the intact endothelial barrier, in VSMCs (70). It has also been reported that exosomes 
containing long noncoding RNA HIF1 alpha-antisense RNA1 (lncRNA HIF1A-AS1) is important 
in atherosclerosis. Wang et al. examined the expression and concentration of exosome-derived 
lncRNA HIF1A-AS1 in atherosclerosis using quantitative real-time polymerase chain reaction 
(qRT-PCR) using plasma samples of patients with atherosclerosis and healthy adults. They 
demonstrated that the expression and concentration of exosomal lncRNA HIF1A-AS1 was 
higher in plasma samples from patients with atherosclerosis compared to healthy controls (71).  
 
The role of exosomes in the heart failure (HF) 
   Heart failure (HF) is an inability of the heart to preserve normal cardiac output without 
increased venous filing pressure. The heart failure is characterized by the pulmonary edema 
and dyspnea and fatigue symptoms (72).  
  It has been shown that myocardial microvascular exosomes play an important role in cardiac 
homeostasis. Juni et al. demonstrated that cell-cell interaction between endothelial cells and 
cardiomyocytes is mediated by exosomes-derived signaling contents including vascular 
endothelial growth factor, nitric oxide, and non-coding RNAs. They also reported that exosomes 
transporting non-coding RNAs from endothelial to cardiomyocytes, and vice versa, regulate the 
angiogenic processes in the heart (73). Yang et al. investigated the relationship between 
exosomes-derived circulating miRNA and heart failure-associated myxomatous mitral valve 
disease (MMVD-CHF) by qRT-PCR using exosomes containing miRNA-extracted from plasma 
samples of dogs with MMVD-CHF. They showed that exosomes-derived miRNAs including miR-
181c, miR-495, and miR-9 are highly expressed in plasma samples of dogs with MMVD-CHF 
(74). To further support the over expression of exosome-derived miRNAs in heart failure 
process, Yamaguchi et al. reported that repeated remote ischemic conditioning (RIC) reduce 
MI-induced LV fibrosis by increasing expression of exosomes-derived miR-29a in RIC-treated 
rats (75).  
Furthermore, it has been reported that injection of CDCs to heart failure-preserved ejection 
fraction (HFpEF) rats improves recovery of the diastolic function via reduction of inflammation 
and fibrosis. Cho et al. investigated the effect of CDC-derived exosomes on systolic and 
diastolic function assessed using transthoracic echocardiogram (ECHO) in model of HFpEF in 
Dahl salt-sensitive (DS) rats. They demonstrated that injected CDCs-derived exosomes to 
HFpEF rats reduce the E/E, ratio which indicates an improvement in diastolic function (76).  
 
The role of exosomes in the myocardial ischemia (MI) 
   Myocardial ischemia (MI) is the most common cause of death globally. An MI is detected by a 
changing pattern of serum troponin and electrocardiographic (ECG) findings (77, 78).  
  It has been shown that exosomes, can be protective during the ischemia and reperfusion injury 
that may be associated with a myocardial ischemia. Vicencio et al. investigated the 
cardioprotective effect of exosome-derived components on ischemia reperfusion by protein 
marker expression, nanoparticle tracking analysis, western blotting, and transmission electron 
microscopy using the isolated exosomes from rats and human blood samples. They 
demonstrated that cardiomyocyte-derived exosomes containing HSP70 protect against 
ischemia reperfusion injury via the binding of HSP70 to toll-like receptor (TLR) 4 which result in 
activation of HSP27 in cardiomyocytes (79). To further support the cardioprotective effect of 
mesenchymal stem cells (MSC)-derived exosomes against ischemia reperfusion injury, Lai et al. 
showed that exosomes secreted by MSCs attenuate infarct size by a paracrine effect in a 
myocardial ischemia reperfusion model in mouse (80). It has also been demonstrated that a 
protective effect of exosomes derived from MSCs is mediated by cellular components including 
increasing the adenosine three phosphate (ATP) and nicotine adenine dehydrogenase (NADH) 
levels as well as enhancing the phosphorylation of both Akt and glycogen synthase kinase 
(GSK) 3β, and reducing the phosphorylation of c-JNK after myocardial ischemia reperfusion 
injury in the C57Bl6/J mouse model (81). To further support the role of MSC-derived exosomes 
protective effect against myocardial ischemia reperfusion injury, Zhao et al. examined the 
protective effect of exosomes derived from human umbilical cord mesenchymal stem cells 
(hucMSCs) on cardiac function and apoptosis by using echocardiography and TUNEL staining, 
respectively, following an induced acute myocardial ischemia (AMI) in rats. They reported that 
exosomes derived from hucMSCs attenuate both cardiac dysfunction and fibrosis, as well as 
protect apoptosis of myocardial cells (82).  
Zhang et al. showed that hypoxia increased the number of exosomes derived from H9C2 cells, 
without any changes in the size of exosomes. They reported that some exosomal miRs such as 
miR-152-3P and miR-21-5P were upregulated in hypoxic stress and exhibited anti-apoptotic 
effects. They proposed that some hypoxia stimulated exosomal miRs, such as miR-152-3p and 
let-7i-5p from H9C2 cells played an anti-apoptotic role through the mitochondrial and cell death 
pathways. Taken together, miRs of H9C2 cell-exosomes had cardioprotective effects under 
hypoxic-condition by inhibiting the apoptotic pathway (3). 
Mesenchymal stem cell-derived exosome taken up by endothelial cells were shown to promote 
angiogenesis (18). The cardioprotective effects of MSC-derived exosomes may be associated 
with the stimulation of autophagy in H9C2 cells following stimulation of H2O2 hypoxia. The 
number of exosomes with 50-150 nm in diameter were increased after 24h of H2O2 treatment. 
MSC-exosomes appeared to protect H9C2 cells treated with H2O2. Internalization of the MSC-
exosomes increased cell viability and autophagy, which led to attenuated apoptosis, and 
reduced ROS production (19). Gonzalez-King and colleagues have shown that the 
concentration of exosomes was higher in mesenchymal stem cells cultured medium when 
treated with Hypoxia Inducible Factor-1α (HIF-1α), and the exosomal proteins were associated 
with tissue development and morphogenesis. However, exosomal proteins which secreted by 
HIF-treated MSCs were associated with stabilization and metabolic HIF-1α process (20). 
The characteristics of mesenchymal stem cells and exosomes derived MSC (MSC-exo) have 
been investigated. MSC expressing CD90 are spindle shape and originated from the bone 
marrow, the MSC-Exo cells were cup-shaped and express CD63. Both of MSC and MSC-exo 
could decreased inflammation, inhibited fibrosis and improved cardiac function in the rat 
myocardial infarction model. However, these effects were superior in MSC-Exos rather than 
MSC (21). Furthermore, the morphology of adipose-tissue derived MSC (ADMSC) and exosome 
derived from them has been characterized. ADMSC was spindle shaped, like MSC, with 
markers including CD29, CD44 and CD105. However, the markers of the exosome secreted 
from ADMSC included: CD9, CD63, CD 81 and HSP-70 (16). 
Endometrium-derived mesenchymal stem cells (EnMSCs) could enhanced cardiac function after 
an MI via high exosomal expression in a rat model. Investigation of miR profiles in MSC derived 
from endothelium showed that miRs profile were different from adipose and bone marrow-
derived MSCs. Among various EnMSC miRs including miR-1275, miR-21-5p, miR-23-3p, miR-
3940-5p, miR-4708-3p, miR-548ap-5p, and miR-642b-5, and their expression was confirmed in 
EnMSC, miR-21 had a higher expression. miR-21 had protective effect against ischemic 
myocardium from apoptosis and stimulated angiogenesis. miR-23 in EnMSC-derived exosomes 
could promote angiogenesis in cardiac endothelial cells by activating proangiogenic signaling 
(7).  
    In addition, it has been shown that a cardioprotective effect of exosomes derived from cardiac 
progenitor cell (CPC) elicit oxidative stress through suppression of activated caspase 3/7 in 
cardiomyoblasts cell lines, H9C2, as well as suppress apoptotic cardiomyocyte cells in model of 
myocardial ischemia/reperfusion in mouse in vitro and in vivo, respectively (83).  
   Sluijter and Rooij. examined correlation of the changes in exosomes containing miRNAs types 
derived from CPCs and biological effect of exosome during ischemia injury using analysis of 
miRNA expression profiles in exosomes in mice. They reported that exosomes derived from 
CPCs in hypoxic condition higher levels of several miRNA compared to cardiac progenitor cell-
derived exosomes grown under normoxic conditions and identified 4 clusters of miRNA 
correlate to a biological effect related to the therapeutic benefit (84). Cervio et al. showed that 
exosomes containing miR-146, miR-210, and miR-132 derived from CPC elicit cardioprotective 
and proangiogenic effects on apoptosis and angiogenesis of cardiomyocytes via inhibition of 
apoptotic and induction of angiogenic these cells (85) (table1). Moreover, Khan et al. 
determined the effect of exosomes containing miRNAs derived from embryonic stem cells 
(ESCs) on MI using miRNA array in mouse. They reported that exosomes containing miR-294 
increase both neovascularization and cardiomyocyte survival as well as reduce fibrosis post 
infraction (86). 
 
The role of exosomes-derived components in cardiovascular function 
    It has been shown that endothelial-derived exosomes containing HSPA12B, a HSP70 family 
member, improves cardiovascular dysfunction induced by polymicrobial sepsis by increasing the 
expression of tight junction proteins affecting vascular permeability, inhibition of adhesion 
molecule expression and decreasing the infiltration of immune cells into the myocardium which 
is mediated by miR-126 derived from exosome (87).  
Kang and coworkers showed that extracellular vesicles secreted from adipose-tissue derived 
stem cells (ASCs) promoted migration and tube formation in vitro. This proangiogenic effect is 
mediated by miR-31 that targeted FIH1 in vascular endothelial cells. Most of the RNA in EVs 
were <200 nucleotides long. However, most RNAs in ASC are large. On the other hand, 
bioanalyzer RNA analysis demonstrated that cellular contamination is minimal which is 
associated with lack of 18s and 28s ribosomal RNA extracellular vesicles. In line with this, it has 
been reported that miRNA is enriched whereas almost all of small RNA (sRNA) is in a narrow 
range of 10-40 nucleotides (88). Therefore, several studies indicate that miR-31 is only 
proangiogenic miRNA (89, 90). Li et al. showed that the exosomes from endothelial progenitor 
cell (EPCs) exhibited angiogenic properties. These exosomes could be taken up by endothelial 
cells and activated angiogenic programs which exhibited its role in vascular regeneration. The 
pro-angiogenic genes including endothelial nitric oxide synthase (eNOS), interleukin-8 (IL-8), 
angiopoietin-1 (ANG-1) and E-selectin were increased more than 4-fold after treated cultured 
human microvascular endothelial cell lines (HMEC), with EPC-derived exosomes. Besides, 
VEGFA, VEGFR-2, hypoxia inducible factor 1 alpha (HIF-1α), chemokine (C-X-C motif) ligand-
16 (CXCL16) and platelet-derived growth factor alpha polypeptide (PDGFA) were upregulated 
by more than 1.5 fold (91).  
Chang et al. identified that miR-146a-5p and miR-146b-5p could take up by endothelial colony-
forming cells both in a free-form and within exosomes. Both inhibited angiogenic ability such as 
endothelial cell migration and tube formation (92). Other investigations also showed that 
injection of miR-155-rich exosomes into mice fed a high fat diet led to significant increase in 
miR-155 expression in the aortae and cause to plaque formation and severe impairment of 
endothelial integrity. On the other hand, adding of miR-155-rich exosomes to cultured 
endothelial cells, reduced the proliferation and migration of miR-155-rich exosome-treated 
endothelial cells, and also the ability of endothelial tube formation was lost. Therefore, miR-155 
has anti-angiogenic effects on ECs. Furthermore, miR-155-rich exosomes led to a reduced 
expression of tight junction (TJ) proteins particularly zonula occludens-1 (ZO-1), so 
mesenchymal stem cell derived miR-155 cause to damage the endothelial barrier function (4). 
In vitro investigation showed that neutral sphingomyelinase 2 (nSMase2) contributed to 
exosome secretion by human cardiosphere-derived cells (hCDCs) by triggering the budding of 
exosomes into multivesicular bodies. hCDCs have markers including CD90 and CD105 
(mesenchymal markers), CD63 and HSP90 (exosomal markers), GATA4 and Nkx2.5 (markers 
of early cardiac development) and could be internalized by endothelial cells, cardiac fibroblasts 
and myocytes. hCDCs exosomes could increase endothelial migration, tub formation and 
branch point complexity, while reduced the human cardiac fibroblast proliferation (93). Secreted 
exosomes by cardiomyocytes in ischemic condition could increase mouse cardiac endothelial 
cell proliferation, endothelial cells migration, sprouting and capillary-like structures. 
Investigations showed that miR-222 of ischemic exosome is responsible for pro-angiogenic 
effects in exosome and led to tube formation and sprouting (94) (table2).   
Beltrami and coworkers isolated exosomes from pericardial fluid (PF). They suggested that the 
cells of the heart and heart vessels could produce miRs which are transported to the PF via 
exosomes. PF-derived exosomes were able to induce the formation of capillary-like cellular 
network on Matrigel. Let-7b-5p is one the highly expressed miRs in the PF-exosomes. It 
induced angiogenesis and improved capillary-like tube formation on Matrigel (95). 
Conclusion 
Extracellular vesicles comprise apoptotic bodies, microvesicles and exosomes, and they 
perform as key regulators in cell-to-cell communication in normal as well as diseased states. 
The extracellular vesicles contain natural cargo molecules, such as miRNA, mRNA and 
proteins, and transfer these functional cargos to neighboring cells or more distant cells through 
circulation. These functionally active molecules then affect distinct signaling cascades. The 
message conveyed to the recipient cells is dependent upon the composition of the extracellular 
vesicle, which is determined by the parent cell and the biogenesis of the extracellular vesicle. 
Because of their properties such as high stability and long half-life in the circulation, 
biocompatibility, low immunogenicity and toxicity, extracellular vesicles have attracted attention 
as putative delivery systems for therapeutics. It is interesting that exosomes from different cells 
may exhibit protective or destructive roles in cardiovascular diseases. The advanced technics to 
modify or load therapeutics into exosomes can be developed and standardized in a future study. 
It is undeniable that the unique opportunities and new challenges for characterization of 
exosomes as clinical biomarkers, diagnosis and prognosis factors in cardiovascular disease are 
an exciting prospect. 
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Table 1 Exosomes and different kinds of cardiovascular diseases  
cardiovascular 
diseases 
Cell-derived 
exosomes 
exosomes-
derived 
contents 
Mechanisms Authors 
C
ar
di
om
yo
pa
th
y 
CDCs miR-148a 
• Improving the heart failure and survival as 
well as enhancing the maximal exercise 
capacity 
• Suppression of LV adverse remodeling 
and reduction of scar size and scar mass 
 
• Aminzadeh et 
al. (2015) 
• Gallet et al. 
(2015) 
 
Endothelial cells NADPH 
Induction of cell death and cardiac 
dysfunction by internalization of 
exosomes 
Monteiro et al. 
(2017) 
Overexpression 
of HSP20 
 
 
• Attenuation of cardiac dysfunction, 
hypertrophy, fibrosis, microvascular 
rarefaction via direct interaction between 
HSP20 and Tgs101 
• Enhancing the cardiac blood vessel 
density and reduction of myocardial 
fibrosis 
• Improving the cardiac dysfunction and 
angiogenesis 
• Wang et al. 
(2016) 
 
 
• Wang et al. 
(2014) 
 
• Gu et al. 
(2015) 
 
At
he
ro
sc
le
ro
si
s 
Dendritic cells  
Enhancing the HUVEC inflammation and 
atherosclerotic lesion through NF-κB 
signaling pathway 
Gao et al. 
(2016) 
VSMCs miR-155 
Stimulation of endothelial permeability and 
progression of atherosclerotic plaque by 
destroying the tight junction and 
endothelial barrier integrity 
Zheng et al. 
(2017) 
H
ea
rt 
fa
ilu
re
 Endothelial cells Non-coding RNAs 
Regulation of angiogenic processes in 
heart 
Juni et al. 
(2017) 
Plasma samples 
miR-181c, 
miR-495, 
miR-9 
Correlation between overexpression of 
these miRNAs and MMVD-CHF 
Yang et al. 
(2017) 
Overexpression 
of miR-29a  
Reduction of left ventricular fibrosis 
induced by MI 
Yamaguchi et 
al. (2015) 
M
yo
ca
rd
ia
l i
sc
he
m
ia
 
(M
I) 
Cardiomyocytes  HSP70 Protection of ischemia reperfusion injury via binding of HSP70 to TLR-4 
Vicencio et al. 
(2015) 
MSCs  
• Attenuation of infract size via paracrine 
effect of exosomes derived from MSCs 
• Increasing the ATP and NADH levels, 
• Lai et al. 
(2010) 
 
enhancing the phosphorylation both of 
Akt and GSK-3β, reducing the 
phosphorylation of c-JNK 
• Arslan et 
al. (2013) 
 
 
hucMSCs  
Attenuation of function and fibrosis of 
cardiac and protection of apoptotic 
myocardia cells 
Zhao et al. 
(2015) 
 
 
Table 2 miRs of exosomes. 
microRNAs place role ref 
miR-1 50% placed in 
Urine exosomes. 
50% placed in urine 
supernatant. 
Biomarker in AMI  
(both increased) 
Cheng et al. 
miR-24, 133a, 
133b,  
Increased after 
CABG surgery. 
 
• Biomarker in surgery 
• Its elevation is associated with hs-cTn-I.  
Emanueli at al. 
miR-210, 132 CPC-EV Inhibition of apoptosis in HL-1 cells Barile et al. 
miR-451 CPC-exosome • A GATA responsive miR 
• Inhibition of H2O2-induced apoptosis by 
reducing the level of caspase 3/7 
Chen et al. 
 
 
miR-19a, miR-
451 
MSC with 
overexpression of 
GATA-4 
• reduce infarct size 
• anti-apoptotic miR 
Yu et al. 
miR-152-3p, 
miR-21-5p  
 
H9C2 cell exosome Anti-apoptotic Zhang et al. 
miR-23 EnMSC-derived 
exosomes 
Promote angiogenesis Ibrahim et al. 
miR-146a-5p,  
miR-146b-5p 
endothelial 
colony-forming 
cells 
Inhibition of angiogenesis Chang et al. 
miR-155 
 
MSC- exosome • Inhibition of angiogenesis 
• Suppression of cardiac fibroblast proliferation 
• decrease the expression of tight TJ 
• suppressed the cardiac fibroblast proliferation 
• it promoted inflammation in cardiac fibroblast 
Zheng et al. 
 
 
 
Wang et al. 
Let-7b-5p PF-exosome • Angiogenesis effect 
• Improve capillary-like tube formation 
Beltrami et al. 
miR-31 ASCs-EV Pro-angiogenic effect Kang et al. 
miR-222 Secreted exosomes 
by cardiomyocytes 
in ischemic 
condition 
pro-angiogenic effect  Ribeiro-
Rodrigues et al. 
miR-29a MI-induced rats 
with RIC exosome 
anti-fibrosis effect Yamaguchi et al. 
 
Figure legend 1: schematic exosome synthase of process and different it’s effects on 
cardiovascular disease  
 
